Skip to content
PatentWorld
Chapter 06

Patent Law & Policy

Legislation and jurisprudence shaping the patent system

The patent system operates within a dynamic legal and institutional context. Over the past half century, landmark legislation, Supreme Court decisions, and policy changes have fundamentally reshaped the rules governing patents — who may obtain them, what subject matter is patent-eligible, and how patents may be enforced. These legal shifts have had substantial effects on patenting behavior, with observable impacts on the trends documented throughout this book.

The timeline below chronicles the most consequential changes to United States patent law and policy from 1980 to the present. Each event entry includes a description of its impact and references to published academic research examining its effects.

Legislation
Court
Policy
International
1980
1982
1984
1994
1995
1998
1999
2003
2006
2007
2010
2011
2013
2014
2017
2018
2021
2025

Impact on Patent Activity

Several of the legal events documented above exhibit observable effects on the patent data examined in earlier chapters:

  • Bayh-Dole Act (1980): Coincided with a substantial increase in university patenting, though scholars debate whether the Act catalyzed the trend or formalized an existing one. Government-funded patents (Public Investment) began rising in the 1980s as universities established technology transfer offices.
  • Court of Appeals for the Federal Circuit (1982): Unified and strengthened patent rights, a change widely cited as a factor in the upward trend in patent grants through the 1990s and 2000s (Patent Count).
  • State Street Bank v. Signature Financial Group (1998): Established the patentability of business methods. The subsequent acceleration in software patent filings is consistent with this ruling, observable as the acceleration of Section G (Physics) and H (Electricity) patents in the late 1990s (Patent Fields).
  • America Invents Act (2011): Created the PTAB inter partes review system, providing a faster and cheaper alternative to litigation for challenging patent validity. The shift to first-inventor-to-file changed priority rules for all patents filed after March 2013.
  • Alice Corp. v. CLS Bank International (2014): The Court held that abstract ideas implemented on generic computers are not patent-eligible under 35 U.S.C. § 101, substantially narrowing patent eligibility. This holding may have contributed to a moderation in software-related patenting in subsequent years, though Sections G and H continued to grow in absolute terms.

The Patent Pipeline

The efficiency of the patent system in processing inventions warrants examination. Comparing the number of patent applications filed each year against the grants issued allows tracking of the USPTO's throughput and the growing gap between filing and granting activity. The ratio of grants to applications indicates how the system's selectivity and backlog have evolved over time.

Figure 1

Successfully Granted Applications Grew From 66,000 (1976–1979 Average) to 349,000 (2019)

Annual patent applications (by filing date) and grants (by grant date) with the grant-to-application ratio. The grant-to-application ratio fell from over 100% in the mid-1970s to 66% by 1997, consistent with increasing examination lag.

The figure displays annual filings (by filing date) and grants (by grant date) for utility patents, with the grant-to-application ratio. Only patents that were eventually granted appear in this dataset. The growing gap between applications and grants since the mid-1990s reflects the increasing duration between filing and grant.
Major legislative changes coincide with observable inflection points in patent filing data, consistent with a relationship between policy and innovation incentives. The growing gap between applications and grants is consistent with increasing examination complexity and backlog.

Alice Impact by Art Group

The Alice Corp. decision (2014) restricted patent eligibility for abstract ideas implemented on generic computers. Despite widespread concern that the ruling would curtail software patenting, an aggregate comparison of software patents against a control group shows continued growth in both patent counts and claim complexity. To assess the impact more precisely, this section then examines Alice-affected USPTO art groups (treatment) against unaffected art groups (control), with values indexed to 2013 = 100.

Figure 2

Alice Corp. Did Not Halt Software Patent Growth: Treatment Reached 157% of 2013 Baseline by 2020

Patent count and mean claims indexed to 2013 = 100: software patents versus control group, 2008–2020

Patent count and mean claim count for Alice-affected art groups (treatment) versus unaffected art groups (control), indexed to 2013 = 100. The vertical reference line marks the Alice Corp. v. CLS Bank decision (June 2014).
Figure 3

Alice-Affected Art Groups Continued Growing Post-2014, Reaching 129.2 by 2024 versus 102.7 for Controls

Patent grants indexed to 2013 = 100 for Alice-affected (treatment) and unaffected (control) art groups, 2008–2024

Patent grant counts indexed to 2013 = 100 for USPTO art groups most affected by Alice Corp. v. CLS Bank (treatment) and unaffected art groups (control). The vertical reference line marks the 2014 Alice decision. Despite the eligibility restriction, treatment groups continued to grow, suggesting that the decision moderated but did not reverse the trend.
The Alice decision was not associated with a sharp decline in patent grants for affected art groups. Instead, treatment group grants continued to outpace controls, reaching 129.2 (indexed) by 2024 compared to 102.7 for controls, suggesting that applicants adapted their claims to survive Section 101 scrutiny.
Figure 4

Pendency Declined Faster for Alice-Affected Art Groups, Falling to 978 Median Days by 2023 versus 1,114 for Controls

Median examination pendency in days for Alice-affected (treatment) and unaffected (control) art groups, 2008–2024

Median pendency (days from filing to grant) for Alice-affected and control art groups. Both groups experienced declining pendency over the period, but the treatment group declined more steeply, potentially reflecting faster resolution of Section 101 issues during prosecution.
The faster pendency decline in Alice-affected art groups suggests that the Alice framework, while initially disruptive, may have streamlined examination by providing clearer grounds for eligibility determinations.

Terminal Disclaimers

A A legal mechanism in which a patent owner voluntarily shortens a patent's term to match a related earlier patent, typically to overcome an obviousness-type double patenting rejection. Terminal disclaimers tie the enforceability of the later patent to the earlier one. is a mechanism by which a patent owner voluntarily limits the patent's enforceable life to match that of a related patent, typically filed to overcome a double-patenting rejection. The rate of terminal disclaimer usage provides insight into patent portfolio strategy: higher rates suggest more intensive efforts to obtain overlapping patent claims on related inventions.

Figure 5

Terminal Disclaimer Rate Peaked at 11.3% in 2023 After Rebounding From a Late-1990s Trough

Share of granted patents with a terminal disclaimer by grant year, 1976–2024

Terminal disclaimer rate computed as the percentage of granted patents that include a terminal disclaimer. The rate dropped sharply in the late 1990s (coinciding with the GATT patent term change) before rebounding and rising to record levels in the 2010s-2020s, consistent with the growth of continuation and patent family strategies.
The secular rise in terminal disclaimer rates since the early 2000s is consistent with the increasing use of continuation applications and patent family strategies, as firms seek to maintain overlapping patent protection across related inventions.
Figure 6

H (Electricity) and C (Chemistry) Lead Terminal Disclaimer Rates at 9.2% and 8.6%

Terminal disclaimer rate by CPC section for patents granted 2015–2024, showing technology-specific variation in portfolio strategy

Terminal disclaimer rates by CPC section. Electricity (H) and Chemistry (C) lead, consistent with the intense patent portfolio strategies employed in semiconductors, telecommunications, and pharmaceuticals. Mechanical engineering fields (B, F) exhibit the lowest rates.
The technology-specific variation in terminal disclaimer rates reflects different patent strategies: electronics and pharmaceutical firms employ continuation-based portfolio building more aggressively than firms in mechanical engineering domains.

Patent Term Adjustment

When the USPTO delays in examining a patent application beyond statutory deadlines, the patent term is extended through Patent Term Adjustment (PTA). The median PTA provides a measure of examination delay beyond what the statute envisions as timely processing. Tracking PTA over time reveals the USPTO's evolving capacity to meet statutory examination timelines.

Figure 7

Median Patent Term Adjustment Peaked at 520 Days in 2011, Declining to 147 Days by 2025 (Through September)

Median patent term adjustment in days by grant year, 2002–2025, tracking USPTO examination delays

Median PTA in days for granted patents by year. PTA increased substantially through the 2000s as the USPTO backlog grew, peaking at 520 days in 2011. Subsequent reforms and hiring initiatives were followed by a sustained decline, though PTA remains well above zero, indicating ongoing examination delays beyond statutory timelines.
The rise and fall of median PTA mirrors the USPTO backlog crisis and subsequent reforms. The peak of 520 days in 2011 represents nearly 1.5 years of additional patent life granted as compensation for examination delays.
Figure 8

Section A (Human Necessities) Receives the Longest PTA at 237 Median Days

Median patent term adjustment in days by CPC section for patents granted 2002–2025, revealing technology-specific examination delays

Median PTA by CPC section. Human Necessities (A), which includes pharmaceuticals and biotechnology, experiences the longest delays at 237 median days, consistent with the complex examination requirements in these domains. Mechanical Engineering (F) and Electricity (H) receive the shortest adjustments.
The technology-specific variation in PTA is consistent with differential examination complexity: pharmaceutical and biotechnology patents require more specialized review and face longer pendency, while mechanical and electrical patents benefit from more established examination practices.

Having examined the legal and policy framework that governs the patent system, the analysis turns to the role of public investment in shaping innovation. The following chapter investigates how government funding and public research expenditures have shaped patenting activity, and what the evolving relationship between federal investment and patent output reveals about the foundations of the innovation ecosystem.

Data coverage: January 1976 through September 2025. All 2025 figures reflect partial-year data.